ProKidney to Participate in Fireside Chat at the Jefferies Healthcare Conference
June 01, 2023 16:05 ET
|
ProKidney
WINSTON-SALEM, N.C., June 01, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic...
ProKidney Reports First Quarter Financial Results and Recent Corporate Highlights
May 11, 2023 16:01 ET
|
ProKidney
WINSTON-SALEM, N.C., May 11, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic...
ProKidney to Present at the BofA Securities Health Care Conference 2023
May 04, 2023 06:05 ET
|
ProKidney
WINSTON-SALEM, N.C., May 04, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease...
ProKidney Reports Fourth Quarter Financial Results and Recent Corporate Highlights
March 28, 2023 16:12 ET
|
ProKidney
WINSTON-SALEM, N.C., March 28, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic...
ProKidney to Participate in TD Cowen’s 43rd Annual Health Care Conference
March 03, 2023 06:05 ET
|
ProKidney
WINSTON-SALEM, N.C., March 03, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease...
ProKidney Announces Publication of Trial Design for Phase 2 Multicenter Clinical Trial of REACT for Late Stage 4 Diabetes-Related Chronic Kidney Disease
January 10, 2023 16:05 ET
|
ProKidney
- Article published online in the Journal of Blood Purification; to be included in future print edition - WINSTON-SALEM, N.C., Jan. 10, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK)...
ProKidney to Present at the J.P. Morgan 41st Annual Healthcare Conference
December 22, 2022 06:05 ET
|
ProKidney
WINSTON-SALEM, N.C., Dec. 22, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease...
ProKidney Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
November 14, 2022 06:05 ET
|
ProKidney
WINSTON-SALEM, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic...
ProKidney to Participate in Upcoming Investor Conferences
November 11, 2022 16:05 ET
|
ProKidney
WINSTON-SALEM, N.C., Nov. 11, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease...
ProKidney Receives Allowance from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for proact 1 (REGEN-006) and EMA Scientific Advice on Phase 3 Protocols of REACT for Diabetic Chronic Kidney Disease
November 03, 2022 06:05 ET
|
ProKidney
WINSTON-SALEM, N.C., Nov. 03, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease...